An open label, cross-over study of the new phosphate binder RenaGel in the management of hyperphosphatemia in ESRD patients.
ASN 30th Annual Meeting, San Antonio
J Am Soc Nephrol (Oct) 8:548A 1997
This is an 8 center study of 85 ESRD patients who underwent a 2 week wash out period and were randomized to received either RenaGel (RG) or calcium acetate (CA) for 8 weeks during which the dose was titrated to control phosphorus. There was then another 2 week washout followed by an 8 week crossover. Both agents lowered phosphorus equally well. The serum calcium levels were higher with CA. Hypercalcemia occurred in 48% of patients treated with CA and 16% of patients on RG. Both RG and CA reduced PTH levels compared to baseline. There were no significant or serious adverse events related to the medications in either group. They conclude that RG is a highly effective phosphorus binder and will be a uniquely useful agent in the treatment of hyperphosphatemia in ESRD.
Comment: It is not stated if these are HD or PD patients, what the dialysate calcium was, what the dose of each agent was, or what the definition of hypercalcemia was. Nonetheless, there is increasing evidence that RG will prove to be very useful in phosphorus control especially in those ESRD patients prone to hypercalcemia or undergoing treatment with calcitriol. (James A. Delmez, M.D., Washington University, St. Louis)
To go back use the BACK button on your browser. Otherwise click on the desired link to this article below:
ASN 30th Annual Meeting, San Antonio
CRF by problem area : Bone disease/aluminum